Climb Bio FY2026 Earnings Forecast Boosted by HC Wainwright

Climb Bio, Inc. (NASDAQ:CLYM) – HC Wainwright lifted their FY2026 EPS estimates for Climb Bio in a research note issued to investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.74) for the year, up from their prior forecast of ($0.76). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Climb Bio’s Q4 2026 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS and FY2027 earnings at ($0.97) EPS.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02.

Several other analysts also recently weighed in on the stock. Mizuho upgraded shares of Climb Bio to a “strong-buy” rating in a report on Wednesday, September 16th. Raymond James Financial restated a “strong-buy” rating on shares of Climb Bio in a research note on Thursday, November 5th. Wedbush upped their price target on Climb Bio from $25.00 to $27.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Robert W. Baird raised their price target on Climb Bio from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on Climb Bio in a research note on Tuesday, October 20th. They issued a “buy” rating and a $28.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $28.14.

Climb Bio Stock Performance

NASDAQ:CLYM opened at $11.74 on Wednesday. The stock has a market capitalization of $689.61 million, a P/E ratio of -14.32 and a beta of 0.01. The company has a 50 day moving average price of $11.80 and a 200 day moving average price of $10.53. Climb Bio has a fifty-two week low of $1.63 and a fifty-two week high of $18.33.

Insider Transactions at Climb Bio

In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the sale, the director directly owned 467,969 shares in the company, valued at $6,397,136.23. This represents a 17.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming acquired a new position in shares of Climb Bio in the third quarter valued at approximately $31,000. Legal & General Group Plc purchased a new stake in Climb Bio during the 2nd quarter worth approximately $45,000. Spark Investment Management LLC purchased a new stake in Climb Bio during the 2nd quarter worth approximately $177,000. The Manufacturers Life Insurance Company lifted its holdings in Climb Bio by 11.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 156,317 shares of the company’s stock worth $1,071,000 after buying an additional 15,700 shares in the last quarter. Finally, Profund Advisors LLC acquired a new stake in Climb Bio during the 3rd quarter worth approximately $190,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.